All Stories

  1. rhPTH(1-84) for hypoparathyroidism: a randomized study of patient-reported outcomes

    Article • European Journal of Endocrinology, July 2025, Oxford University Press (OUP)

    Ansgar Heck

  2. Pasireotide as first line medical therapy for selected patients with acromegaly

    Article • Pituitary, April 2025, Springer Science + Business Media

    Ansgar Heck

  3. Indocyanine green fluorescence in endoscopic transsphenoidal resection of pituitary neuroendocrine tumors: a systematic review

    Article • Acta Neurochirurgica, March 2025, Springer Science + Business Media

    Ansgar Heck

  4. Precision Medicine in Acromegaly: The Potential of Multimodal Therapy

    Article • The Journal of Clinical Endocrinology & Metabolism, September 2024, Endocrine Society

    Ansgar Heck

  5. No effect of surgery on kidney and cardiovascular risk factors in mild primary hyperparathyroidism: secondary analyses from a 10-year randomized controlled trial

    Article • European Journal of Endocrinology, August 2024, Oxford University Press (OUP)

    Ansgar Heck

  6. Acromegaly management in the Nordic countries: A Delphi consensus survey

    Article • Clinical Endocrinology, June 2024, Wiley

    Ansgar Heck

  7. Unravelling pituitary tumours in medically treated patients with acromegaly: the impact of systematic MRI reassessment

    Article • Acta Radiologica, April 2024, SAGE Publications

    Ansgar Heck

  8. Long-term depot specific changes in adipose tissue after treatment of acromegaly

    Article • European Journal of Endocrinology, February 2024, Oxford University Press (OUP)

    Ansgar Heck

  9. Endocortical Trabecularization in Acromegaly: The Cause for the Paradoxically Increased Vertebral Fracture Risk?

    Article • JBMR Plus, August 2023, Oxford University Press (OUP)

    Ansgar Heck

  10. Endoskopisk firehåndsteknikk ved hypofysesvulster

    Article • Tidsskrift for Den norske legeforening, June 2023, Norwegian Medical Association

    Ansgar Heck

  11. TGFBR3L is associated with gonadotropin production in non-functioning gonadotroph pituitary neuroendocrine tumours

    Article • Pituitary, March 2023, Springer Science + Business Media

    Ansgar Heck

  12. Gene expression profiling of subcutaneous adipose tissue reveals new biomarkers in acromegaly

    Article • European Journal of Endocrinology, March 2023, Oxford University Press (OUP)

    Ansgar Heck

  13. Trends in incidence and mortality risk for acromegaly in Norway: a cohort study

    Article • Endocrine, December 2022, Springer Science + Business Media

    Ansgar Heck

  14. Mortality and Morbidity in Mild Primary Hyperparathyroidism: Results From a 10-Year Prospective Randomized Controlled Trial of Parathyroidectomy Versus Observation

    Article • Annals of Internal Medicine, June 2022, American College of Physicians

    Ansgar Heck

  15. Sex difference in patients with controlled acromegaly—A multicentre survey

    Article • Clinical Endocrinology, May 2022, Wiley

    Ansgar Heck

  16. Current clinical practice for thromboprophylaxis management in patients with Cushing’s syndrome across reference centers of the European Reference Network on Rare Endocrine Conditions (Endo-ERN)

    Article • Orphanet Journal of Rare Diseases, May 2022, Springer Science + Business Media

    Ansgar Heck

  17. European expert consensus on practical management of specific aspects of parathyroid disorders in adults and in pregnancy: recommendations of the ESE Educational Program of Parathyroid Disorders (PARAT 2021)

    Article • European Journal of Endocrinology, February 2022, Oxford University Press (OUP)

    Ansgar Heck

  18. The Influence of DXA Hardware, Software, Reference Population and Software Analysis Settings on the Bone Mineral Density and T-Score Relationship

    Article • Journal of Clinical Densitometry, January 2022, Elsevier

    Ansgar Heck

  19. Silent, isolated ACTH deficiency in malignant melanoma patients treated with immune checkpoint inhibitors

    Article • BMJ Case Reports, May 2021, BMJ

    Ansgar Heck

  20. Effects of Parathyroidectomy on Quality of Life: 10 Years of Data From a Prospective Randomized Controlled Trial on Primary Hyperparathyroidism (the SIPH ‐Study)

    Article • Journal of Bone and Mineral Research, November 2020, Wiley

    Ansgar Heck

  21. Hip Structure Analyses in Acromegaly: Decrease of Cortical Bone Thickness After Treatment: A Longitudinal Cohort Study

    Article • JBMR Plus, October 2019, Oxford University Press (OUP)

    Ansgar Heck

  22. MANAGEMENT OF ENDOCRINE DISEASE: Individualised management of acromegaly

    Article • European Journal of Endocrinology, August 2019, Oxford University Press (OUP)

    Ansgar Heck

  23. Parathyroid hormone independent hypercalcemia in adults

    Article • Best Practice & Research Clinical Endocrinology & Metabolism, October 2018, Elsevier

    Ansgar Heck

  24. The effect of surgery on fat mass, lipid and glucose metabolism in mild primary hyperparathyroidism

    Article • Endocrine Connections, August 2018, Bioscientifica

    Ansgar Heck

  25. Targeting either GH or IGF-I during somatostatin analogue treatment in patients with acromegaly: a randomized multicentre study

    Article • European Journal of Endocrinology, October 2017, Bioscientifica

    Professor Jens Otto Lunde Jorgensen, Ansgar Heck

  26. Effect of Surgery Versus Observation: Skeletal 5-Year Outcomes in a Randomized Trial of Patients With Primary HPT (the SIPH Study)

    Article • Journal of Bone and Mineral Research, July 2017, Wiley

    Mikael Hellström , Ansgar Heck

  27. Treatment of acromegaly increases BMD but reduces trabecular bone score: a longitudinal study

    Article • European Journal of Endocrinology, August 2016, Bioscientifica

    Ansgar Heck

  28. Insulin sensitivity, body composition and adipose depots following 12 w combined endurance and strength training in dysglycemic and normoglycemic sedentary men

    Article • Archives of Physiology and Biochemistry, July 2016, Taylor & Francis

    Ansgar Heck

  29. Treatment of acromegaly increases BMD but reduces Trabecular Bone Score - a longitudinal study

    Article • Endocrine Abstracts, May 2016, Bioscientifica

    Ansgar Heck

  30. MR-undersøkelse predikerer behandlingsrespons ved akromegali

    Article • Tidsskrift for Den norske legeforening, January 2016, Norwegian Medical Association

    Ansgar Heck

  31. MRI T2 characteristics in somatotroph adenomas following somatostatin analog treatment in acromegaly

    Article • Endocrine, November 2015, Springer Science + Business Media

    Ansgar Heck

  32. Quantitative analyses of T2-weighted MRI as a potential marker for response to somatostatin analogs in newly diagnosed acromegaly

    Article • Endocrine, October 2015, Springer Science + Business Media

    Ansgar Heck

  33. Effects of Parathyroidectomy Versus Observation on the Development of Vertebral Fractures in Mild Primary Hyperparathyroidism

    Article • The Journal of Clinical Endocrinology & Metabolism, April 2015, Endocrine Society

    Ansgar Heck

  34. The Metabolic Risk in Patients Newly Diagnosed with Acromegaly Is Related to Fat Distribution and Circulating Adipokines and Improves after Treatment

    Article • Neuroendocrinology, January 2015, Karger Publishers

    Ansgar Heck

  35. Metabolic improvement after treatment of acromeglay is determined by the increase of gynoid fat mass and the decrease of serum vaspin and IGF1

    Article • Endocrine Abstracts, April 2014, Bioscientifica

    Ansgar Heck

  36. Expression of SSTR2a, but not of SSTRs 1, 3, or 5 in Somatotroph Adenomas Assessed by Monoclonal Antibodies Was Reduced by Octreotide and Correlated With the Acute and Long-Term Effects of Octreotide

    Article • The Journal of Clinical Endocrinology & Metabolism, November 2013, Endocrine Society

    Ansgar Heck

  37. Epithelial Splicing Regulator Protein 1 and Alternative Splicing in Somatotroph Adenomas

    Article • Endocrinology, September 2013, Endocrine Society

    Ansgar Heck

  38. Attenuated RORC Expression in the Presence of EMT Progression in Somatotroph Adenomas following Treatment with Somatostatin Analogs Is Associated with Poor Clinical Recovery

    Article • PLOS One, June 2013, PLOS

    Ansgar Heck

  39. Differential effect of octreotide treatment on expression of sstr2a, 3 and 5 in somatotroph adenomas

    Article • Endocrine Abstracts, April 2013, Bioscientifica

    Ansgar Heck

  40. Intensity of pituitary adenoma on T2‐weighted magnetic resonance imaging predicts the response to octreotide treatment in newly diagnosed acromegaly

    Article • Clinical Endocrinology, June 2012, Wiley

    Ansgar Heck

  41. Adenoma granulation pattern correlates with clinical variables and effect of somatostatin analogue treatment in a large series of patients with acromegaly

    Article • Clinical Endocrinology, December 2011, Wiley

    Ansgar Heck

  42. Simple model for the effectiveness of PDT with pulsed-laser sources

    Article • August 1994, SPIE

    Ansgar Heck

  43. Photodynamische Therapie mit Photosan 3 und mikrosekunden Laserpulsen

    Article • January 1994, Springer Science + Business Media

    Ansgar Heck